What happened with SRRK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Scholar Rock’s lead drug candidate, apitegromab, is intended to treat the muscles of people with spinal muscular atrophy (SMA) alongside their existing approved treatment. The antibody blocks activation of myostatin in skeletal muscle. The company is also developing SRK-439 for rare, severe neuromuscular diseases.
Scholar Rock has no approved products and has not earned revenue from product sales. Equity issuances, research collaboration payments and borrowings have primarily funded its work. Its intended sales business depends on apitegromab gaining approval, doctors prescribing it as an additional treatment, and health insurers and other payors covering and reimbursing it.
Manufacturing is a central dependency. Scholar Rock owns no manufacturing facilities and relies on single-source suppliers for apitegromab’s drug substance and final filling and finishing. The FDA withheld approval because of deficiencies at the outside fill-finish facility, not concerns about the drug’s efficacy or safety data. Scholar Rock plans to resubmit after the facility resolves those deficiencies and is advancing work at a second fill-finish site.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Scholar Rock’s prospects hinge chiefly on apitegromab winning approval and use alongside existing SMA therapies such as Roche’s risdiplam, while standing apart from muscle-targeted rivals such as NMD Pharma.
Biogen sells SPINRAZA to the SMA patients Scholar Rock aims to treat, but apitegromab is intended to add muscle-targeted treatment to existing SMN therapy rather than replace it. Watch Biogen’s high-dose nusinersen formulation as the treatment options for those patients evolve.
Ionis’s SPINRAZA, sold worldwide by Biogen, treats the same SMA patients Scholar Rock targets with apitegromab as an add-on therapy. Ionis also has preclinical FSHD efforts, worth watching as Scholar Rock develops apitegromab for that disease.
Keros offers a competing route to increasing muscle mass: it develops molecules that capture signaling proteins, called ActRII ligand traps, while Scholar Rock develops antibodies that selectively inhibit myostatin activation. Watch whether Keros’s muscle-and-bone candidates can avoid effects on blood vessels, a concrete test of how its approach differs.
Novartis sells SMN-directed SMA treatment to the patient population Scholar Rock hopes to reach with muscle-directed apitegromab, intended for use alongside approved SMN therapy. Watch its additional onasemnogene abeparvovec formulation, which was in late-stage development as of Scholar Rock’s 2025 filing.
Dyne’s FSHD program competes for a disease market Scholar Rock is pursuing with apitegromab, alongside Dyne’s broader work on rare muscle diseases. Watch FSHD development progress rather than product sales: Dyne had no commercialized candidates as of December 31, 2025.
Biogen Inc. earningsBIIB
Biogen’s report will show how demand for SPINRAZA is faring among people with SMA, the patient group Scholar Rock hopes to reach with apitegromab added to SMN-directed treatment.
Watch what Biogen says about SPINRAZA sales and the progress of its high-dose formulation. Stable or growing sales would indicate that the existing base of patients on SMN-directed treatment remains in place; weakening sales would put that base in question. Apitegromab is intended as an add-on, not a replacement, so Biogen’s report informs the treatment landscape but cannot establish demand for apitegromab.
Dyne Therapeutics, Inc. earningsDYN
Dyne Therapeutics’ report will show how its FSHD program is progressing, as it and Scholar Rock pursue the same patient population and limited clinical-trial resources.
Look for reported progress in Dyne’s FSHD clinical development, not product sales; as of Scholar Rock’s 2025 filing, Dyne had no commercialized candidates. Clear progress would show a rival program advancing in the same disease area and could intensify competition for patients and trial resources. A setback would ease that near-term pressure, but would not establish apitegromab’s efficacy or approval prospects.
Keros Therapeutics, Inc. earningsKROS
Keros Therapeutics’ report will show whether its muscle-and-bone candidates can avoid vascular effects, testing a distinct muscle-building approach alongside Scholar Rock’s myostatin-targeting strategy.
Watch for progress in Keros’s muscle-and-bone candidates and any reported vascular effects. Progress without such effects would show that a different muscle-building approach is advancing; vascular concerns or stalled programs would weaken that competitive signal. Neither outcome settles the safety or effectiveness of Scholar Rock’s own candidates.
Scholar Rock Holding Corporation earningsThis company
Scholar Rock’s report will show whether spending to advance apitegromab and its other programs is using up the funds it needs for development and a potential launch.
Read operating expenses alongside cash, cash equivalents and marketable securities. Controlled expense growth with substantial funds remaining would support the company’s stated runway into 2027. Faster expense growth and a marked decline in funds would point to earlier financing or program cuts, putting more pressure on apitegromab’s development and potential launch.
